Oleclumab (MEDI9447) epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) novel combination study

Exclusion Criteria

• 1. Receipt of an EGFR TKI within 14 days of the first dose of study treatment
• 2. Receipt of any conventional or investigational anticancer therapy not otherwise specified within 21 days of the planned first dose
• 3. Prior receipt of any investigational immunotherapy. Participants may have received agents that have local health authority approval for the disease indication
• 4. Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed.
• 5. Participants with a history of venous thrombosis within the past 3 months
• 6. Participants with prior history of myocardial infarction, transient ischemic attack, or stroke in the last 6 months
• 7. Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment
• 8. Other invasive malignancy within 2 years
• 9. Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression
• 10. Current or prior use of immunosuppressive medication within 14 days prior to the first dose
• Additional Exclusion Criteria for Arm A
• 1. Concurrent treatment (or inability to stop therapy) with medications or herbal supplements known to be potent inducers of cytochrome P (CYP) 3A4
• 2. Participants has a history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD
• 3. Participants requires continuous supplemental oxygen for any reason
• Additional Exclusion Criteria for Arm B
• 1. Herbal preparations/medications are not allowed throughout the study
• 2. History of seizures excluding those that occurred due to previously untreated CNS metastasis